Stoke Therapeutics
Eric Olson currently serves as the Chief Business Officer at Stoke Therapeutics. Previously, Eric held the position of Vice President and Head of Business Development at Alnylam Pharmaceuticals. Alongside this, Eric has extensive experience in global business development, having worked as Vice President and Head of Rare Disease & Immunology Global Business Development at Takeda. Additionally, Eric has been involved in strategic transactions as the Head of Ophthalmics & Internal Medicine Transactions at Shire and served as Senior Director of Corporate Development at AGTC.
This person is not in any teams
This person is not in any offices
Stoke Therapeutics
Stoke Therapeutics is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression.